HBV antiviral therapy has the potential to reduce the burden of HBV-related liver disease by suppressing HBV DNA replication to undetectable levels, reducing the progression of liver fibrosis and reducing the risk of hepatocellular carcinoma (HCC) development. Treatment outcomes and long-term benefits require adherence to medication regimens. This study aimed to identify the prevalence and factors associated with non-adherence to antiviral therapy.
Methods
A cross-sectional survey of patients receiving HBV antiviral therapies was conducted in three Sydney hospitals. Participants were asked to complete an online questionnaire. Logistic regression was used to assess the associations between non-adherence (defined as missing more than 1 day of medication in the last 30 days) and demographic, socio-economic, disease, treatment, healthcare system and individual-related factors.
Results
Of the 277 participants, 66 (23.8%) were non-adherent, missing a mean 1.7 days of medication (sd 4.8) in the last 30 days. In multivariate analysis, non-adherent behaviour declined with age (odds ratio [OR] 0.9, 95% CI 0.97, 0.99; P<0.013). Participants who reported having no established routine to take their medication (OR 5.0, 95% CI 1.4, 17.4; P<0.012) and having inadequate health literacy (OR 2.7, 95% CI 1.3, 5.5; P<0.007) were more likely to be non-adherent.
Conclusions
Almost a quarter of participants in the current study were non-adherent. Adherence is potentially modifiable through person-centred education, collaborative models of patient care and interventions designed to improve health literacy and establish medication routines. Findings have the potential to improve health service delivery to patients at risk of non-adherence to HBV antiviral therapy.
References
1.
LavanchyD.Chronic viral hepatitis as a public health issue in the world.Best Pract Res Clin Gastroenterol2008; 22: 991–1008.
2.
LavanchyD.Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.J Viral Hepat2004; 11: 97–107.
IloejeU.H., YangH.I., ChenC.J.Natural history of chronic hepatitis B: what exactly has REVEAL revealed?Liver Int2012; 32: 1333–1341.
5.
SuzukiY., SuzukiF., KawamuraY.Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?J Gastroenterol Hepatol2009; 24: 429–435.
KardasP., LewekP., MatyjaszczykM.Determinants of patient adherence: a review of systematic reviews.Front Pharmacol2013; 4: 91.
8.
LieveldF.I., van VlerkenL.G., SiersemaP.D., van ErpecumK.J.Patient adherence to antiviral treatment for chronic hepatitis B and C: a systematic review.Ann Hepatol2013; 12: 380–391.
9.
GelladW.F., GrenardJ.L., MarcumZ.A.A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity.Am J Geriatr Pharmacother2011; 9: 11–23.
10.
ChotiyaputtaW., PetersonC., DitahF., GoodwinD., LokA.Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B.J Hepatol2011; 54: 12–18.
11.
SogniP., CarrieriM.P., FontaineH.The role of adherence in virological suppression in patients receiving anti-HBV analogues.Antivir Ther2012; 17: 395–400.
12.
ChotiyaputtaW., HongthanakornK., OberhelmanR.Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs.J Viral Hepat2012; 19: 205–212.
13.
DahlT.F., CowieB.C., BiggsB-A. Health literacy in patients with chronic hepatitis B attending a tertiary hospital in Melbourne: a questionnaire based survey.BMC Infect Dis2014; 14: 537.
14.
GiangL., SelingerC.P., LeeA.U.Evaluation of adherence to oral antiviral hepatitis B treatment using structured questionnaires.World J Hepatol2012; 4: 43–49.
15.
van VlerkenL.G., ArendsP., LieveldF.I.Real life adherence of chronic hepatitis B patients to entecavir treatment.Dig Liver Dis2015; 47: 577–583.
16.
PengJ., YinJ., CaiS., YuT., ZhongC.Factors associated with adherence to nucleos(t)ide analogs in chronic hepatitis B patients: results from a 1-year follow-up study.Patient Prefer Adherence2015; 9: 41–45.
17.
BaeJ.W., GuyerW., GrimmK., AlticeF.L.Medication persistence in the treatment of HIV infection: a review of the literature and implications for future clinical care and research.AIDS2011; 25: 279–290.
PolisS., Zablotska-ManosI., ZekryA., MaherL.Adherence to hepatitis B antiviral therapy: a qualitative study.Gastroenterol Nurs2017; 40: 239–246.
20.
ChesneyM.A., IckovicsJ.R., ChambersD.B.Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instruments.AIDS Care2000; 12: 255–266.
21.
EngelbergR., DowneyL., CurtisJ.R.Psychometric characteristics of a quality of communication questionnaire assessing communication about end-of-life care.J Palliat Med2006; 9: 1086–1098.
22.
WeissB.D., MaysM.Z., MartzW.Quick assessment of literacy in primary care: the newest vital sign.Ann Fam Med2005; 3: 514–522.
23.
KesslerR.C., AndrewsG., ColpeL.J.Short screening scales to monitor population prevalences and trends in non-specific psychological distress.Psychol Med2002; 32: 959–976.
24.
WhiteB., MaddenA., PrinsM.Assessing the feasibility of hepatitis C virus vaccine trials: results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study.Vaccine2014; 32: 5460–5467.
25.
LokA., McMahonB.AASLD practice guideline update: Chronic hepatitis B.Hepatology2009; 50: 1–36.
HongthanakornC., ChotiyaputtaW., OberhelmanK.Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.Hepatology2011; 53: 1854–1863.
28.
LeeM.Adherence with use of oral agents in the treatment of chronic hepatitis B.Curr Hepat Rep2012; 11: 70–74.
29.
KamezakiH., KandaT., WuS.Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.Scandinavian Journal of Gastroenterology2011; 46: 1111–1117.
30.
WangJ., WangM., HuangY.Acute liver failure resulting from discontinuation of nucleoside analogues in chronic hepatitis B patients: a report of two cases.Scand J Infect Dis2013; 45: 158–160.
31.
LabaT.L., LehnbomE., BrienJ., JanS.Understanding if, how and why non-adherent decisions are made in an Australian community sample: a key to sustaining medication adherence in chronic disease?Res Social Adm Pharm2015; 11: 154–162.
32.
AtkinsL., FallowfieldL.Intentional and non-intentional non-adherence to medication amongst breast cancer patients.Eur J Cancer2006; 42: 2271–2276.
33.
GadkariA.S., McHorneyC.A.Unintentional non-adherence to chronic prescription medications: how unintentional is it really?BMC Health Serv Res2012; 12: 98.
34.
MukhtarO., WeinmanJ., JacksonS.H.D.Intentional non-adherence to medications by older adults.Drugs Aging2014; 31: 149–157.
35.
LabaT.L., BrienJ.A., JanS.Understanding rational non-adherence to medications. A discrete choice experiment in a community sample in Australia.BMC Fam Pract2012; 13: 61.
36.
TordoffJ., SimonsenK., ThomsonW.M., NorrisP.T.‘It's just routine.’ A qualitative study of medicine-taking amongst older people in New Zealand.Pharm World Sci2010; 32: 154–161.
37.
ChambersJ.A., O'CarrollR.E., HamiltonB.Adherence to medication in stroke survivors: a qualitative comparison of low and high adherers.Br J Health Psychol2011; 16: 592–609.
38.
KumarasamyN., SafrenS.A., RaminaniS.R.Barriers and facilitators to antiretroviral medication adherence among patinets with HIV in Chennai, India: a qualitative study.AIDS Patient Care STDs2005; 19: 526–537.
39.
RyanG.W., WagnerG.J.Pill taking ‘routinization’: a critical factor to understanding episodic medication adherence.AIDS Care2003; 15: 795–806.
40.
BorgsteedeS.D., WestermanM.J., KokI.L.Factors related to high and low levels of drug adherence according to patients with type 2 diabetes.Int J Clin Pharm2011; 33: 779–787.
41.
SandersM.J., Van OssT.Using daily routines to promote medication adherence in older adults.Am J Occup Ther2013; 67: 91–99.
42.
Australian Bureau of Statistics. Health Literacy, Australia 2006. Canberra: 2008 Contract No.: 4233.0. (Accessed 1 June 2015.) Available from http://www.abs.gov.au/ausstats/abs@.nsf/Latestproducts/4233.0Main%20Features22006.
RatzanS.C.Health literacy: communication for the public good.Health Promot Int2001; 16: 207–214.
45.
HuffC.Does your patient really understand?Hosp Health Netw2011; 85: 34–5, 7-8, 2.
46.
OstiniR., KairuzT.Investigating the association between health literacy and non-adherence.Int J Clin Pharm2014; 36: 36–44.
47.
CastroC.M., WilsonC., WangF., SchillingerD.Babel babble: physicians’ use of unclarified medical jargon with patients.Am J Health Behav2007; Suppl 1: S85–S95.
48.
EastonP., EntwistleV.A., WilliamsB.Health in the ‘hidden population’ of people with low literacy. A systematic review of the literature.BMC Public Health2010; 10: 459.
49.
VillaireM., MayerG.Low health literacy: the impact on chronic illness management.Prof Case Manag2007; 12: 213–216.
50.
EastonP., EntwistleV.A., WilliamsB.How the stigma of low literacy can impair patient-professional spoken interactions and affect health: insights from a qualitative investigation.BMC Health Serv Res2013; 13: 319.
51.
HennekensC., BurningJ.Statistical association and cause effect relationships. In: MayrentS., editor. Epidemiology in Medicine.20 ed. Philadelphia, USA: Lippincott Williams & Wilkins; 1987. p. 30–51.
52.
HilleretM., LarratS., Stanke-LabesqueF., LeroyV.Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough?J Hepatol2011; 55: 1468–1469.
